10x Genomics (NASDAQ:TXG - Free Report) had its price target trimmed by Morgan Stanley from $28.00 to $26.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.
Other analysts also recently issued reports about the company. Citigroup decreased their price objective on 10x Genomics from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, February 13th. JPMorgan Chase & Co. reduced their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group lowered their target price on 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of "Hold" and a consensus target price of $20.57.
Get Our Latest Stock Analysis on 10x Genomics
10x Genomics Trading Down 1.9 %
Shares of TXG traded down $0.24 during trading hours on Friday, reaching $12.07. 3,593,761 shares of the company traded hands, compared to its average volume of 2,551,476. The stock's fifty day moving average price is $14.52 and its 200 day moving average price is $17.22. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -7.89 and a beta of 1.85. 10x Genomics has a 12-month low of $10.80 and a 12-month high of $48.42.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. On average, research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.
Institutional Investors Weigh In On 10x Genomics
A number of large investors have recently made changes to their positions in TXG. KBC Group NV grew its stake in 10x Genomics by 38.8% during the 3rd quarter. KBC Group NV now owns 3,225 shares of the company's stock valued at $73,000 after purchasing an additional 902 shares during the last quarter. Atria Wealth Solutions Inc. lifted its holdings in shares of 10x Genomics by 9.6% during the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after purchasing an additional 943 shares during the period. First Horizon Advisors Inc. boosted its position in 10x Genomics by 53.3% in the third quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after buying an additional 1,012 shares during the last quarter. Blue Trust Inc. raised its position in 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after buying an additional 1,025 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock valued at $35,000 after acquiring an additional 1,265 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
